Product Images Capecitabine
View Photos of Packaging, Labels & Appearance
- Label- Capecitabine Tablets USP 150 mg - capecitabine150mglabel
- Label- Capecitabine Tablets USP 500 mg - capecitabine500mglabel
- capecitabinechemicalstructure - capecitabinechemicalstructure
- capecitabinefigure1 - capecitabinefigure1
- capecitabinefigure2 - capecitabinefigure2
- capecitabinefigure3 - capecitabinefigure3
- capecitabinefigure4 - capecitabinefigure4
- capecitabinefigure5 - capecitabinefigure5
Product Label Images
The following 8 images provide visual information about the product associated with Capecitabine NDC 68001-643 by Bluepoint Laboratories, such as packaging, labeling, and the appearance of the drug itself. This resource could be helpful for medical professionals, pharmacists, and patients seeking to verify medication information and ensure they have the correct product.
Label- Capecitabine Tablets USP 150 mg - capecitabine150mglabel
This text provides information about capecitabine tablets containing 150mg of the active ingredient. It includes details on dosage, administration instructions, storage conditions, and manufacturer information. The tablets should be taken whole with water within 30 minutes of a meal and should not be crushed or cut. The medication is classified as a cytotoxic agent and should be stored at 20-25°C. Contact information for the US distributor is also provided along with manufacturing details.*
Label- Capecitabine Tablets USP 500 mg - capecitabine500mglabel
This text is a description of capecitabine tablets containing 500 mg of capecitabine USP. The tablets are film-coated and should be swallowed whole with water within 30 minutes of a meal. It is emphasized not to crush or cut the tablets and to store them in tight containers at a temperature between 20°C to 25°C (68°F to 77°F). Capecitabine is noted as a cytotoxic agent and a hazardous drug. The manufacturer is Hetero Labs Limited in India, and the contact number for the U.S. is provided as 1-866-495-1995. The prescription is only available with an NDC code of 68001-644-07. Additional details mention instructions for patients, the dispensing of tablets, and the recommended dosage as per prescribing information.*
capecitabinefigure3 - capecitabinefigure3
This text mentions estimated probabilities, a range from 1.0 to 0.0, and a treatment regimen using 5-FU and Leucovorin known as the Mayo Regimen with Capecitabine dosage specified at 1250 mg/sqm twice daily intermittently.*
capecitabinefigure4 - capecitabinefigure4
This is a chart showing estimated probabilities for different doses of Docetaxel and Capecitabine over time in days. It illustrates how the probability changes with different dosage levels.*
capecitabinefigure5 - capecitabinefigure5
This is a table showing estimated probabilities for different time scenarios in a medical context. It includes dosages for Docetaxel and Capecitabine for the treatment cycle.*
* The product label images have been analyzed using a combination of traditional computing and machine learning techniques. It should be noted that the descriptions provided may not be entirely accurate as they are experimental in nature. Use the information in this page at your own discretion and risk.